Financhill
Sell
50

PRPO Quote, Financials, Valuation and Earnings

Last price:
$9.62
Seasonality move :
-1.19%
Day range:
$9.00 - $10.15
52-week range:
$3.90 - $10.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.74x
P/B ratio:
1.29x
Volume:
9K
Avg. volume:
13.4K
1-year change:
68.53%
Market cap:
$15.1M
Revenue:
$18.5M
EPS (TTM):
-$2.08

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PRPO
Precipio
-- -- -- -- --
AKYA
Akoya Biosciences
$19.3M -$0.23 -21.86% -14.82% $1.88
AZTA
Azenta
$140.8M $0.07 -13.41% 86.12% $41.60
BNGO
Bionano Genomics
$6.3M -$1.11 -11.23% -97.97% $7.33
BRKR
Bruker
$772.5M $0.44 1.31% 799.94% $55.13
HBIO
Harvard Bioscience
$19.2M -$0.04 -18.82% -64.29% $3.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PRPO
Precipio
$9.96 -- $15.1M -- $0.00 0% 0.74x
AKYA
Akoya Biosciences
$1.22 $1.88 $60.8M -- $0.00 0% 0.76x
AZTA
Azenta
$27.10 $41.60 $1.2B -- $0.00 0% 2.06x
BNGO
Bionano Genomics
$3.70 $7.33 $12.4M -- $0.00 0% 0.16x
BRKR
Bruker
$36.97 $55.13 $5.6B 71.10x $0.05 0.54% 1.62x
HBIO
Harvard Bioscience
$0.28 $3.00 $12.6M -- $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PRPO
Precipio
1.82% 1.177 2.3% 0.46x
AKYA
Akoya Biosciences
108.34% 0.070 110.41% 0.36x
AZTA
Azenta
-- 2.222 -- 2.16x
BNGO
Bionano Genomics
21.3% -0.388 150.7% 0.82x
BRKR
Bruker
53.77% 0.828 33.24% 0.66x
HBIO
Harvard Bioscience
70.79% 2.159 143.69% 0.34x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PRPO
Precipio
$2.1M -$859K -24.83% -25.53% -17.43% -$182K
AKYA
Akoya Biosciences
$9.9M -$13.3M -52.81% -338.02% -78.8% -$7.4M
AZTA
Azenta
$65.9M -$12.6M -3.48% -3.48% -8.77% $7M
BNGO
Bionano Genomics
$2.9M -$8.5M -112.51% -141.6% -46.62% -$2.8M
BRKR
Bruker
$391.2M $65.7M 2.11% 4.53% 4.77% $39M
HBIO
Harvard Bioscience
$12.2M -$1.5M -62.88% -103.83% -229.6% $2.3M

Precipio vs. Competitors

  • Which has Higher Returns PRPO or AKYA?

    Akoya Biosciences has a net margin of -17.94% compared to Precipio's net margin of -94.07%. Precipio's return on equity of -25.53% beat Akoya Biosciences's return on equity of -338.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPO
    Precipio
    43.42% -$0.59 $11.9M
    AKYA
    Akoya Biosciences
    59.33% -$0.32 $70.6M
  • What do Analysts Say About PRPO or AKYA?

    Precipio has a consensus price target of --, signalling upside risk potential of 90.76%. On the other hand Akoya Biosciences has an analysts' consensus of $1.88 which suggests that it could grow by 54.3%. Given that Precipio has higher upside potential than Akoya Biosciences, analysts believe Precipio is more attractive than Akoya Biosciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPO
    Precipio
    0 0 0
    AKYA
    Akoya Biosciences
    0 7 0
  • Is PRPO or AKYA More Risky?

    Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Akoya Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock PRPO or AKYA?

    Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akoya Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Akoya Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPO or AKYA?

    Precipio quarterly revenues are $4.9M, which are smaller than Akoya Biosciences quarterly revenues of $16.6M. Precipio's net income of -$884K is higher than Akoya Biosciences's net income of -$15.7M. Notably, Precipio's price-to-earnings ratio is -- while Akoya Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.74x versus 0.76x for Akoya Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPO
    Precipio
    0.74x -- $4.9M -$884K
    AKYA
    Akoya Biosciences
    0.76x -- $16.6M -$15.7M
  • Which has Higher Returns PRPO or AZTA?

    Azenta has a net margin of -17.94% compared to Precipio's net margin of -28.21%. Precipio's return on equity of -25.53% beat Azenta's return on equity of -3.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPO
    Precipio
    43.42% -$0.59 $11.9M
    AZTA
    Azenta
    45.94% -$0.88 $1.7B
  • What do Analysts Say About PRPO or AZTA?

    Precipio has a consensus price target of --, signalling upside risk potential of 90.76%. On the other hand Azenta has an analysts' consensus of $41.60 which suggests that it could grow by 53.51%. Given that Precipio has higher upside potential than Azenta, analysts believe Precipio is more attractive than Azenta.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPO
    Precipio
    0 0 0
    AZTA
    Azenta
    1 5 0
  • Is PRPO or AZTA More Risky?

    Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

  • Which is a Better Dividend Stock PRPO or AZTA?

    Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPO or AZTA?

    Precipio quarterly revenues are $4.9M, which are smaller than Azenta quarterly revenues of $143.4M. Precipio's net income of -$884K is higher than Azenta's net income of -$40.5M. Notably, Precipio's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.74x versus 2.06x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPO
    Precipio
    0.74x -- $4.9M -$884K
    AZTA
    Azenta
    2.06x -- $143.4M -$40.5M
  • Which has Higher Returns PRPO or BNGO?

    Bionano Genomics has a net margin of -17.94% compared to Precipio's net margin of -48.04%. Precipio's return on equity of -25.53% beat Bionano Genomics's return on equity of -141.6%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPO
    Precipio
    43.42% -$0.59 $11.9M
    BNGO
    Bionano Genomics
    45.5% -$1.15 $61.2M
  • What do Analysts Say About PRPO or BNGO?

    Precipio has a consensus price target of --, signalling upside risk potential of 90.76%. On the other hand Bionano Genomics has an analysts' consensus of $7.33 which suggests that it could grow by 98.2%. Given that Bionano Genomics has higher upside potential than Precipio, analysts believe Bionano Genomics is more attractive than Precipio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPO
    Precipio
    0 0 0
    BNGO
    Bionano Genomics
    0 2 0
  • Is PRPO or BNGO More Risky?

    Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

  • Which is a Better Dividend Stock PRPO or BNGO?

    Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPO or BNGO?

    Precipio quarterly revenues are $4.9M, which are smaller than Bionano Genomics quarterly revenues of $6.5M. Precipio's net income of -$884K is higher than Bionano Genomics's net income of -$3.1M. Notably, Precipio's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.74x versus 0.16x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPO
    Precipio
    0.74x -- $4.9M -$884K
    BNGO
    Bionano Genomics
    0.16x -- $6.5M -$3.1M
  • Which has Higher Returns PRPO or BRKR?

    Bruker has a net margin of -17.94% compared to Precipio's net margin of 2.17%. Precipio's return on equity of -25.53% beat Bruker's return on equity of 4.53%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPO
    Precipio
    43.42% -$0.59 $11.9M
    BRKR
    Bruker
    48.82% $0.11 $4B
  • What do Analysts Say About PRPO or BRKR?

    Precipio has a consensus price target of --, signalling upside risk potential of 90.76%. On the other hand Bruker has an analysts' consensus of $55.13 which suggests that it could grow by 49.12%. Given that Precipio has higher upside potential than Bruker, analysts believe Precipio is more attractive than Bruker.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPO
    Precipio
    0 0 0
    BRKR
    Bruker
    5 8 0
  • Is PRPO or BRKR More Risky?

    Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

  • Which is a Better Dividend Stock PRPO or BRKR?

    Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.54% to investors and pays a quarterly dividend of $0.05 per share. Precipio pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PRPO or BRKR?

    Precipio quarterly revenues are $4.9M, which are smaller than Bruker quarterly revenues of $801.4M. Precipio's net income of -$884K is lower than Bruker's net income of $17.4M. Notably, Precipio's price-to-earnings ratio is -- while Bruker's PE ratio is 71.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.74x versus 1.62x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPO
    Precipio
    0.74x -- $4.9M -$884K
    BRKR
    Bruker
    1.62x 71.10x $801.4M $17.4M
  • Which has Higher Returns PRPO or HBIO?

    Harvard Bioscience has a net margin of -17.94% compared to Precipio's net margin of -231.19%. Precipio's return on equity of -25.53% beat Harvard Bioscience's return on equity of -103.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    PRPO
    Precipio
    43.42% -$0.59 $11.9M
    HBIO
    Harvard Bioscience
    55.96% -$1.14 $50.8M
  • What do Analysts Say About PRPO or HBIO?

    Precipio has a consensus price target of --, signalling upside risk potential of 90.76%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 955.22%. Given that Harvard Bioscience has higher upside potential than Precipio, analysts believe Harvard Bioscience is more attractive than Precipio.

    Company Buy Ratings Hold Ratings Sell Ratings
    PRPO
    Precipio
    0 0 0
    HBIO
    Harvard Bioscience
    1 1 0
  • Is PRPO or HBIO More Risky?

    Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

  • Which is a Better Dividend Stock PRPO or HBIO?

    Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PRPO or HBIO?

    Precipio quarterly revenues are $4.9M, which are smaller than Harvard Bioscience quarterly revenues of $21.8M. Precipio's net income of -$884K is higher than Harvard Bioscience's net income of -$50.3M. Notably, Precipio's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.74x versus 0.14x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PRPO
    Precipio
    0.74x -- $4.9M -$884K
    HBIO
    Harvard Bioscience
    0.14x -- $21.8M -$50.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
57
TNXP alert for May 29

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Buy
70
AGFY alert for May 29

Agrify [AGFY] is up 18.95% over the past day.

Buy
87
SMR alert for May 29

NuScale Power [SMR] is down 0.37% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock